Oxford Biomedica cuts 2026 revenue guidance as clients delay orders

Oxford BioMedica cut 2026 revenue guidance to £180 million–£200 million after clients deferred orders and a US manufacturing site took longer than expected to come online. The update signals demand and execution headwinds into next year, though the company still provided a full-year range rather than withdrawing guidance.

Analysis

Oxford BioMedica cut 2026 revenue guidance to £180 million–£200 million after clients deferred orders and a US manufacturing site took longer than expected to come online. The update signals demand and execution headwinds into next year, though the company still provided a full-year range rather than withdrawing guidance.